K. Nathan Sankar

1.1k total citations
41 papers, 526 citations indexed

About

K. Nathan Sankar is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, K. Nathan Sankar has authored 41 papers receiving a total of 526 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 7 papers in Epidemiology. Recurrent topics in K. Nathan Sankar's work include Cancer Immunotherapy and Biomarkers (14 papers), Lung Cancer Treatments and Mutations (13 papers) and Lung Cancer Research Studies (9 papers). K. Nathan Sankar is often cited by papers focused on Cancer Immunotherapy and Biomarkers (14 papers), Lung Cancer Treatments and Mutations (13 papers) and Lung Cancer Research Studies (9 papers). K. Nathan Sankar collaborates with scholars based in United States, Germany and Canada. K. Nathan Sankar's co-authors include Angel Qin, Shirish M. Gadgeel, Nithya Ramnath, Michael D. Green, Alex K. Bryant, Jing Christine Ye, Wenru Song, Zihai Li, Garth W. Strohbehn and Siwen Hu‐Lieskovan and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

K. Nathan Sankar

36 papers receiving 518 citations

Peers

K. Nathan Sankar
Boyang Chang China
Jason B. Litten United States
A. Reinacher-Schick Germany
Jaume Capdevila Spain
Akio Saiura Japan
Rita P. Dalal United States
Ashish Manne United States
Hiroki Ikezawa Japan
Beate Haugk United Kingdom
Zhen-Hai Lu China
Boyang Chang China
K. Nathan Sankar
Citations per year, relative to K. Nathan Sankar K. Nathan Sankar (= 1×) peers Boyang Chang

Countries citing papers authored by K. Nathan Sankar

Since Specialization
Citations

This map shows the geographic impact of K. Nathan Sankar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Nathan Sankar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Nathan Sankar more than expected).

Fields of papers citing papers by K. Nathan Sankar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Nathan Sankar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Nathan Sankar. The network helps show where K. Nathan Sankar may publish in the future.

Co-authorship network of co-authors of K. Nathan Sankar

This figure shows the co-authorship network connecting the top 25 collaborators of K. Nathan Sankar. A scholar is included among the top collaborators of K. Nathan Sankar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Nathan Sankar. K. Nathan Sankar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Billet, Sandrine, Zhenqiu Liu, Barliz Waissengrin, et al.. (2025). CD105 blockade restores osimertinib sensitivity in drug-resistant EGFR-mutant non-small cell lung cancer. Drug Resistance Updates. 81. 101237–101237. 2 indexed citations
2.
Sankar, K. Nathan, E. S. Williams, Michael A. Thompson, et al.. (2025). DNA damage repair gene alterations influence the tumor immune microenvironment in advanced non-small cell lung cancer. Lung Cancer. 201. 108444–108444.
3.
Beltran, Himisha, Prantesh Jain, Erin L. Schenk, et al.. (2025). 2758MO Updated results from a phase I/II study of gocatamig for small cell lung cancer (SCLC) and other neuroendocrine cancers. Annals of Oncology. 36. S1367–S1367.
4.
5.
Reckamp, Karen L., et al.. (2024). Emerging Targets in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences. 25(18). 10046–10046. 14 indexed citations
6.
Sankar, K. Nathan, Galen Cook‐Wiens, Matthew Modes, & Peter Chen. (2024). Life After Critical Illness: A Descriptive Study of Clinical Characteristics and Discharge Locations of Adults After ICU Hospitalization. A1577–A1577.
7.
Schipper, Matthew J., Lars G. Fritsche, Garth W. Strohbehn, et al.. (2024). Pan‐Cancer Survival Impact of Immune Checkpoint Inhibitors in a National Healthcare System. Cancer Medicine. 13(21). e70379–e70379. 4 indexed citations
8.
Kim, Sungjin, Anthony Nguyen, Mitchell Kamrava, et al.. (2024). Cardiac events and dynamic echocardiographic and electrocardiogram changes following osimertinib treatment in lung cancer. Frontiers in Cardiovascular Medicine. 11. 1485033–1485033. 1 indexed citations
9.
Sankar, K. Nathan, Mary W. Redman, Konstantin H. Dragnev, et al.. (2024). Pragmaticism in Cancer Clinical Trials. American Society of Clinical Oncology Educational Book. 44(3). e100040–e100040. 9 indexed citations
10.
11.
Ji, Jun Ho, Sang Yun Ha, Danbi Lee, et al.. (2023). Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma. International Journal of Molecular Sciences. 24(8). 7640–7640. 13 indexed citations
12.
Edwards, Donna M., K. Nathan Sankar, Matthew J. Schipper, et al.. (2023). Pneumonitis After Chemoradiotherapy and Adjuvant Durvalumab in Stage III Non-Small Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics. 118(4). 963–970. 8 indexed citations
13.
Yeo, Yee Hui, Michael Luu, Walid S. Ayoub, et al.. (2023). COVID-19 Pandemic Impact on Diagnosis, Stage, and Treatment of Hepatocellular Carcinoma in the United States. SHILAP Revista de lepidopterología. 3(2). 230–237. 2 indexed citations
14.
Sankar, K. Nathan, Jun Gong, Arsen Osipov, et al.. (2023). Recent advances in the management of hepatocellular carcinoma. Clinical and Molecular Hepatology. 30(1). 1–15. 67 indexed citations
15.
Bryant, Alex K., K. Nathan Sankar, Lili Zhao, et al.. (2022). De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer. European Journal of Cancer. 171. 55–63. 17 indexed citations
16.
Sankar, K. Nathan, Mina Zeinali, Sunitha Nagrath, & Nithya Ramnath. (2022). Molecular biomarkers and liquid biopsies in lung cancer. Seminars in Oncology. 49(3-4). 275–284. 2 indexed citations
17.
Bryant, Alex K., K. Nathan Sankar, Garth W. Strohbehn, et al.. (2022). Timing of Adjuvant Durvalumab Initiation Is Not Associated With Outcomes in Stage III Non-small Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics. 113(1). 60–65. 13 indexed citations
18.
Bryant, Alex K., K. Nathan Sankar, Garth W. Strohbehn, et al.. (2021). Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancer. Lung Cancer. 163. 35–41. 22 indexed citations
19.
Sankar, K. Nathan, Shirish M. Gadgeel, & Angel Qin. (2020). Molecular therapeutic targets in non-small cell lung cancer. Expert Review of Anticancer Therapy. 20(8). 647–661. 68 indexed citations
20.
Vaduganathan, Muthiah, Erin R. Cleveland, K. Nathan Sankar, et al.. (2017). Plasma Renin Activity, Response to Aliskiren, and Clinical Outcomes in Patients Hospitalized for Heart Failure: The ASTRONAUT Trial. European Journal of Heart Failure. 20(4). 677–686. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Boyang Chang Breakdown of academic impact, for papers by Jason B. Litten Breakdown of academic impact, for papers by A. Reinacher-Schick Breakdown of academic impact, for papers by Jaume Capdevila Breakdown of academic impact, for papers by Akio Saiura Breakdown of academic impact, for papers by Rita P. Dalal Breakdown of academic impact, for papers by Ashish Manne Breakdown of academic impact, for papers by Hiroki Ikezawa Breakdown of academic impact, for papers by Beate Haugk Breakdown of academic impact, for papers by Zhen-Hai Lu
Rankless by CCL
2026